GoodmanL. S., and GilmanA.: The Pharmacological Basis of Therapeutics.MacMillan Co., New York, p. 2, 1965.
2.
Ibid. p. 17
3.
Ibid. p. 3
4.
Ibid. p. 4
5.
Ibid. p. 10
6.
MacGregorA. G.: Clinical Effects of Interaction Between Drugs. Review of Points at Which Drugs Can Interact, Proc. Roy. Soc. Med.58: 943 (Nov.) 1965.
7.
MilneM.D.: Clinical Effects of Interaction Between Drugs. Influence of Acid-Base Balance on Efficacy and Toxicity of Drugs, Proc. Roy. Soc. Med.58: 961 (Nov.) 1965.
8.
References Quoted In Milne (7. Above)
9.
WaddellW. J., and ButlerT. C.: The Distribution and Excretion of Phenobarbital, J. Clin. Invest.36: 1217 (Aug.) 1957.
10.
PayneJ. P., and RoweG. G.: The Effects of Mecamylamine on the Cat as Modified by the Administration of Carbon Dioxide, Brit. J. Pharmacol.12: 555 (Dec.) 1957.
11.
BlackmanJ. G., and RayC.: Actions of Mecamylamine, Dimecamine, Pempidine and Their Two Quaternary Metho-salts at the Neuromuscular Junction, Brit. J. Pharmacol.22: 56 (Feb.) 1964.
12.
BrodieB. B.: Clinical Effects of Interaction Between Drugs. Displacement of One Drug by Another from Carrier or Receptor Sites, Proc. Roy. Soc. Med.58: 946 (Nov.) 1965.
13.
ChristensenL. K., HansenJ. M., and KristensenM.: Sulphaphenazole-Induced Hypoglycemic Attacks in Tolbutamide-Treated Diabetics, Lancet2: 1298 (Dec. 21) 1963.
14.
EisenM. J.: Combined Effect of Sodium Warfarin and Phenylbutazone, J. Am. Med. Assoc.189: 64 (July 6) 1964.
ZubrodC. G., KennedyT. J., and ShannonJ. A.: J. Clin. Invest.27: 114, 1948.
17.
OdellG. B.: Studies on Kernicterus. I. The Protein Binding of Bilirubin, J. Clin. Invest.38: 823 (May) 1959.
18.
SilvermanW. A.: A Difference in Mortality Rate and Incidence of Kernicterus among Premature Infants Allotted to Two Prophylactic Antibacterial Regimens, Pediatrics18: 614 (Oct.) 1956.
19.
HenchP. S.: Reversibility of Certain Rheumatic and Non-rheumatic Conditions by Use of Cortisone or of Pituitary Adrenocorticotropic Hormone, Ann. Internal Med.36: 1 (Jan.) 1952.
20.
MaickelR. P., MillerF. P., and BrodieB. B.: Pharmacologist1: 182, 1965.
21.
GoodmanL.S., and GilmanA.: The Pharmacological Basis of Therapeutics, MacMillan Co., New York, 1965, p. 17.
22.
Ibid. p. 14
23.
BurnsJ. J., and ConneyA. H.: Clinical Effects of Interaction Between Drugs. Enzyme Stimulation and Inhibition in the Metabolism of Drugs, Proc. Roy. Soc. Med.58: 955 (Nov.) 1965.
24.
FoutsJ. R., and RogersL. A.: Morphological Changes in the Liver Accompanying Stimulation of Microsomal Drug-Metabolizing Enzyme Activity by Phenobarbital, Chlordane, Benzpyrene or Methylcholanthrene in Rats. J. Pharmacol. Exptl. Therap.147: 112 (Jan.) 1965.
25.
RemmerH., and MerkerH. J.: [Enzyme Induction and Increase of Endoplasmic Reticulum in Liver Cells during Phenobarbital (Luminal) Therapy], Klin. Wochschr.41: 276 (Mar. 15) 1963.
26.
ConneyA. H., DavisonC., GastelR., and BurnsJ. J.: Adaptive Increases in Drug-Metabolizing Enzymes Induced by Phenobarbital and Other Drugs, J. Pharmacol. Exptl. Therap.130: 1, 1960.
27.
CucinellS. A., ConneyA. H., SansurM., and BurnsJ. J.: Drug Interactions in man. I. Lowering Effect of Phenobabital on Plasma Levels of Bishydroxycoumarin (Dicumarol) and Diphenylhydantoin (Dilantin)Clin. Pharmacol. Therap.6: 420, 1965.
28.
DaytonP. G., et al: J. Clin. Invest.40: 1797, 1961.
29.
BusfieldD., ChildK. J., and TomichE. G.: An Effect of Phenobarbitone on Griseofulvin Metabolism in the Rat, Brit. J. Pharmacol.22: 137 (Feb). 1964.
30.
BusfieldD.: An Effect of Phenobarbitone on Blood Levels of Griseofulvin in Man, Lancet2: 1042 (Nov. 16) 1963.
31.
ChenW., et al.: Life Sci.2: 35, 1962.
32.
HartL. G., ShulticeR. W., and FoutsJ. R.: Stimulatory Effects of Chlordane on Hepatic Microsomal Drug Metabolism in the Rat, Toxicol. Appl. Pharmacol.5: 371 (May) 1963.
33.
BurnsJ.J.: Application of Drug Metabolism to Drug Toxicity Studies, Ann. N.Y. Acad. Sci.123: 273 (Mar. 12) 1965.
34.
ConneyA. H.: Drug-Induced Changes in Steroid Metabolism, Ann. N.Y. Acad. Sci.123: 98 (Mar. 12) 1965.
35.
GilletteJ. R.: Fortschr. Arzneimittel-Forsch.6: 11, 1963.
36.
FoxS. L.: Potentiation of Anticoagulants Caused by Pyrazole Compounds, J. Am. Med. Assoc.188: 320 (Apr. 20) 1964.
37.
WeinerM., et al.: Fed. Proc.24: 153, 1965.
38.
SerroneD. M., and FujimotuJ. M.: The Effect of Certain Inhibitors in Producing Shortening of Hexobarbital Action, Biochem. Pharmacol.11: 609 (July) 1962.
39.
KatoR., ChiesaraE., and VassanelliP.: Further Studies on the Inhibition and Stimulation of Microsomal Drug-Metabolizing Enzymes of Rat Liver by Various Compounds, Biochem. Pharmacol.13: 69 (Jan.) 1964.
40.
GoodmanL. S., and GilmanA.: The Pharmacological Basis of Therapeutics, MacMillan Co., New York, 1965, p. 12.
41.
Ibid. p. 13
42.
Ibid. p. 14
43.
SjögvistF.: Clinical Effects of Interaction Between Drugs. Psychotropic Drugs (2). Interaction Between Monoamine Oxidase (MAO) Inhibitors and Other Substances, Proc. Roy. Soc. Med.58: 967 (Nov.) 1965.
44.
Others
45.
Anon.: Plasma Concentration of Drugs and Their Efficiency, Prescribers' J.6: 48 (Oct.) 1966.
46.
GoodmanL. S., and GilmanA.: The Pharmacological Basis of Therapeutics, MacMillan Co., New York, 1965, p. 15.
47.
MilneM. D.: Clinical Effects of Interaction Between Drugs. Review of Points at Which Drugs Can Interact, Proc. Roy. Soc. Med.58: 943 (Nov.) 1965.
